David D. Ho, MD and Yaoxing Huang, PhD
Dr. Ho is currently Irene Diamond Professor at The Rockefeller University and Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center, a world-renowned biomedical research institute in New York City. He has been at the forefront of AIDS research since the beginning of the epidemic. His seminal studies unveiling the dynamic nature of HIV replication in vivo were published in Nature, Science and the New England Journal of Medicine and revolutionized our basic understanding of the disease. This knowledge led him to champion the groundbreaking approach of combination antiretroviral therapy that resulted in unprecedented control of HIV among patients. To date, more than 14 million patients worldwide have benefitted from combination antiretroviral therapy. As a major driving force in the fight to end the disease, Dr. Ho has received numerous honors and awards for his scientific accomplishments from his academic peers, national governments and the public at large. He is the recipient of a Presidential Citizens Medal, as well as 13 honorary doctorates. In addition to his election to the American Academy of Arts and Sciences and the National Academy of Medicine, he was recognized as Time magazine’s “Man of the Year” in 1996.
Dr. Huang is currently an Associate Professor at the Aaron Diamond AIDS Research Center and has spent 25 years conducting HIV research. He has authored over 30 publications on HIV pathogenesis, vaccine discovery and development, and antibody engineering and development. Dr. Huang has led or contributed to the discovery, characterization, and preclinical development of both DNA and attenuated viral vector vaccines against HIV that were selected for advancement to clinical evaluation. More recently, he has focused his research efforts on the discovery and engineering of bispecific antibodies for HIV prevention, treatment and eradication.
Drs. Ho and Huang have collaborated on several successful scientific projects over the past 20 years and have advanced multiple vaccine and antibody candidates from the bench to the bedside. RenBio’s formation and growth is the fruition of their latest collaborative endeavor.